David Risinger

Joseph Stringer

Seamus Fernandez

Jason Gerberry

Jiale Song

Louise Chen

Roger Song

Salim Syed

Thomas Shrader

Tom Shrader

Umer Raffat

- Vaxcyte's lead pneumococcal conjugate vaccine, **Vax 31**, is progressing to **Phase 3 clinical development** in adults, with the pivotal study initiating in **Q4 2025** and potential market approval anticipated by **2028**.  **[1649094_tx_372950_1]** 
- The company has also reinitiated enrollment in its **Phase 2 Vax 31 infant study** with an optimized dose, with primary series data expected by **mid-2027** or potentially earlier.  **[1649094_tx_372950_5]** 
- Vaxcyte confirmed **FDA approval** of its manufacturing process for Phase 3, a crucial step for commercialization of the complex 31-valent vaccine.  **[1649094_tx_372950_3]** **[1649094_tx_372950_4]** 
- With a strong balance sheet of **$2.8 billion as of June 30**, Vaxcyte has extended its cash runway to fund operations until **2028**, aligning with the anticipated adult Vax 31 approval.  **[1649094_tx_372950_8]**

Vaxcyte Provides Update on Vax 31 Clinical Development and Financial Position

Vaxcyte (PCVX)